Baton Rouge / louisianaradionetwork.com
Jan 29, 2021 2:27 PM
Johnson and Johnson announced today that its one-dose COVID vaccine offers strong protection from the virus with an international average efficacy of 66%. Assistant Dean for Translational Science at LSU Health New Orleans School of Medicine, Doctor Lucio Miele, says however in the U-S the efficacy rate is 72% and only 57% in South Africa.
In addition to being only one injection, Miele says the J&J vaccine does not require cold storage making it ideal for rural areas and for those with access to care issues.
Miele says while the vaccine has a 66-percent efficacy rate of preventing moderate to severe illnesses like pneumonia or other breathing difficulties the efficacy of preventing serious illness is 85-percent.
An FDA advisory committee meets today to discuss whether to give emergency approval to a COVID-19 vaccine developed by Moderna. Assistant Dean for Translational Research at LSU Health New Orleans School of Medicine, Doctor Lucio Miele says the data looks remarkably good.
“As good as what we saw last week from Pfizer.”
The Moderna vaccine could receive FDA approval soon. An advisory panel of the FDA is meeting today looking at Moderna’s trial results. Miele says the data looks remarkably good and the side effects are minor.
“Soreness, chills, aches, sometimes fever but the real adverse effects were really not a concern.”